Fat Loss

Reta + Cagri Blend

Next gen triple agonist + amylin fat loss blend (Retatrutide / Cagrilintide)

Next gen triple agonist meets amylin — the emerging heavyweight fat loss stack.

Vial

15 mg

BAC Water

2 mL

Dose

750 mcg

Units on 1 mL

Timing

Frequency

1x per week

Duration

Until goal weight

Note: Per dose: ~500mcg Retatrutide / 250mcg Cagrilintide

Also sold as

Research chemical vendors can't legally label products with the real name, so Reta + Cagri Blend often appears under coded SKUs. If you're shopping and see any of these, it's the same compound:

CagriSema
Reta+Cagri
3R + Cagri

Codes shown are for identification only.

Your draw

10 units · 750 mcg

On a standard 100-unit / 1 mL insulin syringe.

What it actually is

Combines Retatrutide (GLP-1 + GIP + glucagon triple agonist) with Cagrilintide (amylin analog). Retatrutide already produces the largest weight loss of any incretin in trials; adding amylin extends satiety and may protect lean mass during aggressive cuts.

Highly potent — start at low doses and titrate. GI side effects and fatigue are more common than with sema/cagri.

Why people use it

Maximum effect fat loss protocols
Users who have plateaued on tirzepatide or reta alone
Improved satiety and glucose response vs. reta monotherapy
Weekly dosing convenience

Educational only · Not a vendor claim

How it works

Retatrutide triple agonizes GLP-1, GIP, and glucagon receptors — the glucagon arm adds direct fat oxidation on top of appetite control. Cagrilintide layers amylin driven satiety and lean mass preservation on top.

Health benefits

Largest observed fat loss potential of any current blend
Amylin arm helps preserve lean mass
Improved insulin sensitivity
Reduced hepatic fat

What you'll feel

Aggressive appetite suppression
Weight loss curves steeper than tirzepatide or sema
Improved metabolic markers within weeks

Pros

Cutting edge stack
Weekly dosing
Addresses multiple pathways simultaneously

Cons

Very potent — side effects more common
Long term human safety data still emerging
Requires careful titration

Side effects to know

Nausea, GI upset, fatigue
Increased heart rate in some users
Rare gallbladder issues at higher doses

Best suited for

Users plateaued on tirzepatideAggressive fat loss phases under supervisionMetabolic syndrome casesResearch users comfortable with newer compounds

Educational summary · Not medical advice · Discuss with a qualified clinician

What to expect

Typical timeline

General pattern for the Fat Loss category. Individual response varies.

Week 1
Titrate up slowly. Expect appetite drop, mild nausea, and possible constipation with GLP-1s. Hydrate and lean on fiber.
Weeks 2–4
Steady weight trend down (0.5–1.5 lb/week is healthy). Prioritize protein (~1 g/lb lean mass) to protect muscle.
Weeks 4–8
Body composition visibly shifts. Add resistance training if you haven't — muscle preservation is the whole game.
Weeks 8+
Re-evaluate dose. Consider a maintenance drop or a scheduled break to reset receptor sensitivity.

Was this page helpful?

The reconstitution math

1Reconstitute the 15 mg vial with 2 mL of bacteriostatic water. Tilt — don't shake.
2Concentration becomes 7,500 mcg/mL (7.5 mg/mL).
3For a 750 mcg dose, draw 0.100 mL — that's 10 units on a 1 mL insulin syringe.
4One vial gives you approximately 20 doses.

Reminder: 100 units on an insulin syringe = 1 mL. Always start at half the listed dose for the first week and rotate injection sites between arms, legs, abdomen, and glutes.

Dose log

Dose logging is available for signed-in users. Track today's dose and notes for Reta + Cagri Blend.